MarketPulse

FDA resubmission

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pharming Charts Growth Despite RUCONEST Decline, Bets on Joenja Expansion

Pharming Group's Q1 2026 revenues fell 8% YoY to $72.4M, hurt by RUCONEST decline, but Joenja surged 34%. Company maintains full-year guidance and advances international launches.
PHAR2026 guidancecash flow positive
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for Anktiva

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.
IBRXbladder cancerAnktiva
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges 10% on NK Cell Therapy Manufacturing Milestone

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.
IBRXBBPclinical trialbladder cancer